These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

382 related items for PubMed ID: 34227913

  • 1. Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agent.
    Rastogi A, Hanna RM, Mkrttchyan A, Khalid M, Yaqoob S, Shaffer K, Dhawan P, Nobakht N, Kamgar M, Goshtaseb R, Sarmosyan K, Gnarini M, Wassef O, Lerma E.
    Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1055-1064. PubMed ID: 34227913
    [Abstract] [Full Text] [Related]

  • 2. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease.
    Natale P, Palmer SC, Ruospo M, Saglimbene VM, Strippoli GF.
    Cochrane Database Syst Rev; 2020 Jun 26; 6(6):CD013165. PubMed ID: 32588430
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis.
    Palmer BF.
    Mayo Clin Proc; 2020 Feb 26; 95(2):339-354. PubMed ID: 31668450
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy.
    Schaefer JA, Gales MA.
    Ann Pharmacother; 2016 Jun 26; 50(6):502-10. PubMed ID: 27009290
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE.
    Roger SD, Spinowitz BS, Lerma EV, Singh B, Packham DK, Al-Shurbaji A, Kosiborod M.
    Am J Nephrol; 2019 Jun 26; 50(6):473-480. PubMed ID: 31658466
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy and safety analysis of sodium zirconium cyclosilicate and calcium polystyrene sulfonate on rapid reduction of potassium in moderate to severe hyperkalemia patients with chronic kidney disease without dialysis.
    Fu X, Zhang S, Gao F, Mao N.
    Clin Nephrol; 2024 Oct 26; 102(4):223-231. PubMed ID: 38994592
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].
    Santoro A, Mandreoli M.
    G Ital Nefrol; 2018 May 26; 35(3):. PubMed ID: 29786183
    [Abstract] [Full Text] [Related]

  • 17. The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K+-binder Lokelma for maximisation of RAAS inhibition in CKD patients with heart failure.
    Murphy D, Ster IC, Kaski JC, Anderson L, Banerjee D.
    BMC Nephrol; 2021 Jul 06; 22(1):254. PubMed ID: 34229607
    [Abstract] [Full Text] [Related]

  • 18. Sodium zirconium cyclosilicate (ZS-9) for the treatment of hyperkalemia.
    Rafique Z, Peacock WF, LoVecchio F, Levy PD.
    Expert Opin Pharmacother; 2015 Jul 06; 16(11):1727-34. PubMed ID: 26159448
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.